ANL (Adlai Nortye) Net Margin %: -343.86% (As of Dec. 2025)


What is Adlai Nortye Net Margin %?

Adlai Nortye ANL -1.57% Net Margin % is -343.86% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 946 Biotechnology companies, Adlai Nortye ranks worse than 75.26% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Adlai Nortye's Net Income for the six months ended in Dec. 2025 was $-17.19 Mil. Adlai Nortye's Revenue for the six months ended in Dec. 2025 was $5.00 Mil. Therefore, Adlai Nortye's net margin for the quarter that ended in Dec. 2025 was -343.86%.

The historical rank and industry rank for Adlai Nortye's Net Margin % or its related term are showing as below:

ANL' s Net Margin % Range Over the Past 10 Years
Min: -710.56   Med: -417.26   Max: -123.95
Current: -710.56

ANL's Net Margin % is ranked worse than
75.26% of 946 companies
in the Biotechnology industry
Industry Median: -88.815 vs ANL: -710.56

Adlai Nortye  (NAS:ANL) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Adlai Nortye Net Margin % Related Terms

Adlai Nortye Net Margin % Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye Net Margin % Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
-123.95 0.00 0.00 0.00 -710.56

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 -343.86

ANL vs PHAT, AURA, RLMD: Net Margin % Comparison

For the Biotechnology subindustry, Adlai Nortye's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adlai Nortye Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's Net Margin % distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's Net Margin % falls into.


Adlai Nortye Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Adlai Nortye's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-35.528/5
=-710.56 %

Adlai Nortye's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-17.193/5
=-343.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -343.86% mean?
Adlai Nortye (ANL) has a Net Margin % of -343.86% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #712 out of 946 companies in the Biotechnology industry, placing it in the top 75.3%.
Is Adlai Nortye's Net Margin % too high?
Adlai Nortye's current Net Margin % is -343.86%. Based on the distribution chart, Adlai Nortye ranks #712 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Adlai Nortye's Net Margin % compare to PHAT and AURA?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #712 out of 946 companies for Net Margin %. This places Adlai Nortye in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current Net Margin % is -343.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Net Margin % of -343.86%. The current Net Margin % is -343.86%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Net Margin % is -343.86% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.